Brentwood, Tenn., March 3, 2009-Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a major pharmaceutical company for a national study on the Hepatitis C Virus. The study explores an investigational drug’s effectiveness as a mono-treatment as well as an add-on treatment option for the condition affecting almost 4 million Americans.
According to a report issued by the Center for Disease Control, top notable factors and/or behaviors increase the possibility that someone will contract HCV include:
“There are over 50 trails testing different medical solutions for HCV…over 50. That in conjunction with other difficulty factors shows the immense need for a focused & strategic recruitment effort. We are excited to be partnering on this trial offering customized, executable solutions that will help the sponsor achieve the desired results.” David Fox, Praxis President & CEO adds, “This is also a new partnership for us and we are thrilled to be here and confident in our experience, research and execution strategy put in place that we will see this trail to success.”
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit www.GoPraxis.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.